Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
QIMC Further Derisks Nova Scotia Natural Hydrogen Multi-Gas System with New Thermogenic Gas and Helium Results
Flow Metals Secures Little Gold Creek Headwaters, Completing Strategic Consolidation of Sixtymile Gold District
Highlights Include Iron Values Exceeding 30%, Nickel up to 500 ppm, Cobalt up to 187 ppm and Vanadium up to 1,710 ppm
